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LETTERS TO THE EDITOR
MILLER FISHER SYNDROME: A CASE REPORT
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ABSTRACT
Miller Fisher syndrome is a rare neurological disease that is considered to be a variant of Guillain-Barré 
syndrome. It is characterized by abnormal muscle coordination (ataxia), paralysis of the eye muscles 
(ophthalmoplegia), and absence of the tendon reflexes (areflexia). Additional symptoms include generalized 
muscle weakness and respiratory failure. Symptoms are usually preceded by a viral illness. This paper 
describes a clinical case of the syndrome in a patient who presented primarily with blurred and double 
vision, and gait disturbance.
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INTRODUCTION
Miller Fisher syndrome (MFS) is a variant of 
Guillain-Barré syndrome (GBS). It is character-
ized by symptoms of abnormal muscle coordina-
tion (ataxia), paralysis of the eye muscles (ophthal-
moplegia), and absence of the tendon reflexes (are-
flexia). Some cases only present with total ophthal-
moplegia. MFS is thought to result from an abnor-
mal acute autoimmune reaction to a previous infec-
tion. It was suggested by some researches that the 
IgG anti-GQ1b antibody could be a marker for MFS. 
While GBS affects 1 person in 100 000, MFS is even 
more uncommon, making up 1 in 100 000 000. MFS 
may progress into GBS (1, 2). Unlike GBS, in MFS the 
neurological deficit starts from the upper body parts, 
continuing in a downward direction. The most com-
mon initial presenting symptom is diplopia, caused 
by external ophthalmoplegia (3). The progress of the 
disease continues for approximately 1 week after the 
initial neurologic symptoms, and a slow and gradual 
improvement follows. Symptoms often resolve, with 
full recovery within approximately 6 months. Atax-
ia and ophthalmoplegia resolve earlier, in the first 3 
months after onset. The continuing areflexia, which 
persists in some cases, is not associated with move-
ment disability. Typical complications of GBS such 
as respiratory failure and need for intensive care with 
ventilation are rare in MFS (4).
CASE REPORT
A 47-year-old man was admitted to the First 
Neurological Clinic of St. Marina University Hos-
pital in Varna, Bulgaria. He presented with blurred 
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DISCUSSION
On admission of the patient to the clinic, sever-
al possible differential diagnoses were discussed, in-
cluding CNS infections and demyelinating disease. 
Later, when lumbar puncture was performed and a 
mild albuminocytological dissociation was found, 
attention was focused on inflammatory diseases af-
fecting the peripheral nervous system. Miller Fish-
er syndrome was accepted, taking into account the 
leading symptoms, and supported by the NCS. It 
should be noted that evidence suggests a rather wide 
range of neurological symptoms to be present, and a 
significant overlap to exist in MFS and other forms of 
GBS. Treatment considerations are similar, consist-
ing mainly of IVIG and plasmapheresis. Due to the 
benign course in the present case, the latter was not 
performed. Familiarity with the rare Miller Fisher 
syndrome will help the clinician to establish the di-
agnosis in patients presenting with areflexia, ataxia, 
and ophthalmic symptoms, and to treat accordingly.
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vision that had appeared three days earlier, vertigo, 
disturbed speech, and paraesthesiae in the four ex-
tremities, followed by unstable gait. He had had an 
upper respiratory tract infection 10 days before these 
complaints. His only medical history was of asthma, 
which was well-controlled with salbutamol (inhaler). 
The patient denied smoking, alcohol or drug abuse, 
or exposure to neurotoxins.
The general physical examination of the patient 
was normal. Neurological examination showed lim-
ited ability to move the eyes in all directions, static 
and locomotor ataxia. No other abnormalities were 
noted.
Haematology and chemistry were normal. 
There was no elevation of inflammatory markers 
in the serum. The electrocardiogram demonstrated 
no pathologic findings. The computed tomography 
of the brain was normal. Magnetic resonance imag-
ing (MRI) of the brain was performed, which only 
revealed mildly thickened mucosal tissue in the left 
maxillary sinus due to a chronic sinus disease. Oth-
erwise, there were no areas of contrast enhancement 
or parenchymal abnormalities. Nerve conduction 
studies (NCSs) showed a sural-sparing pattern of 
sensory conduction abnormalities. Serology for HIV 
and syphilis was negative. Cerebrospinal fluid (CSF) 
assessment revealed mildly elevated protein count of 
0.88 mg/dL, which was in line with the diagnosis of 
GBS or MFS. 
In the initial days of the hospitalization the con-
dition of the patient continued to worsen with more 
pronounced limitation of eye movements and gen-
eral discomfort. The patient was started on intrave-
nous immunoglobulins. During the course of treat-
ment he showed some clinical improvement. The fol-
low-up a month after the hospitalization revealed 
that the patient was doing very well, having recov-
ered almost completely. The slowest to resolve were 
his subjective visual disturbances, which were also 
the first symptoms to appear.
